# Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

> **NCT03544125** · PHASE1 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen Receptor Negative
- HER2/Neu Negative
- Progesterone Receptor Negative
- Prognostic Stage IV Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03544125
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-03
- **Primary completion:** 2018-08-07
- **Final completion:** 2020-11-18
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03544125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03544125, "Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03544125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*